Background Non-cirrhotic intrahepatic portal hypertension (NCIPH) is characterized by thrombotic microangiopathy of the portal venous system, low ADAMTS13 (a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs-13), and high vWF (von Willebrand factor) levels. This study aimed to screen for ADAMTS13 mutations, focusing on the CUB domain, in these patients. Methods Prospectively recruited NCIPH patients and healthy volunteers underwent tests for plasma vWF-ADAMTS13 balance. Sanger sequencing of the CUB domain of ADAMTS13 was done in a subset of the NCIPH patients, and the detected mutation was screened for in all the study participants. Nextgeneration sequencing of clinically relevant exome and liver immunostaining for ADAMTS13 was done in patients with detected ADAMTS13 mutation. Results Plasma vWF-ADAMTS13 balance was significantly altered in 24 NCIPH patients (Child's class A:23, B:1) as compared to 22 controls. On initial sequencing of the CUB domain (17 cases and 3 controls), one NCIPH patient showed a rare missense variant (SNV) at position c.3829C >T resulting in p.R1277W (rs14045669). Subsequent RFLP analysis targeted to the R1277W variant did not detect this in any other NCIPH patient, nor in any of the 22 controls.
Introduction
Idiopathic non-cirrhotic intrahepatic portal hypertension (NCIPH) is characterized by occlusion of the small intrahepatic portal vein radicles. Studies from India have shown that NCIPH is an ongoing problem especially in lower socioeconomic strata [1, 2] . We have demonstrated ADAMTS13 (a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs-13) deficiency in patients with NCIPH despite preserved liver function [3, 4] . ADAMTS13, a vWF (von Willebrand factor) cleaving protease secreted mainly from the hepatic stellate cells [5] , and P-selectin, a protein anchoring vWF to the endothelial surface, are involved in primary hemostasis. In this study, we studied vWF-ADAMTS13 balance in these patients.
The ADAMTS13 gene is located on chromosome 9q34 (29 exons) . The ADAMTS13 protein consists of a number of domains including the metalloprotease domain (responsible for cleaving) at the N-terminal and multiple CUB (complement C1r/C1s, urinary epidermal growth factor, and brain natriuretic peptide-1) domains at the C-terminal, which play an important role in the binding of the protein to its substrate [6] .
We have noted lower plasma ADAMTS13 activity in NCIPH patients when the ADAMTS13 activity was assayed using the complete vWF molecule as a substrate (i.e. collagen binding assay) compared to the activity using a synthetic vWF peptide substrate that contains the cleavage site (i.e. FRET or fluorescence resonance transfer assay) [3] . We postulated that this phenomenon reflected defective binding of ADAMTS13 to vWF, a prerequisite for cleavage [7] . Mutations in the CUB domain of ADAMTS13 are associated with decreased activity and also defective secretion of ADAMTS13 from hepatic stellate cells [8] . In this study, we looked for mutations in the CUB domain of the ADAMTS13 gene (exons 26 and 27) in NCIPH patients as compared to healthy controls.
The alternative complement pathway is activated by decreased expression of ADAMTS13 [9] . Unrestrained activation of the alternative complement pathway is one of the mechanisms involved in the pathogenesis of thrombotic microangiopathy [9, 10] . Localized intrahepatic complement activation may also play a role in the pathogenesis of NCIPH. Over-activation of the complement pathway is associated with familial mutations in genes involved in alternative/lectin complement pathways. Recent reports describing mutations in KCNN3 [11] and DGUOK [12] genes in familial NCIPH patients reaffirm the pathogenic role of genetic factors in NCIPH.
In this study, we carried out an evaluation for ADAMTS13-CUB domain mutations in a cohort of NCIPH patients. In a single NCIPH patient with ADAMTS13 CUB domain mutation, detailed genetic analysis (performed by next-generation sequencing of clinically relevant exome) of ADAMTS13, vWF, alternative complement pathways, and KCNN3/ DGUOK was performed.
Methods
A hospital-based case-control study was performed to assess prevalence of mutation(s) in the CUB domain of the ADAMTS13 gene and also assess vWF-ADAMTS13 imbalance and plasma P-selectin in NCIPH patients as compared to healthy volunteers. In an NCIPH patient with ADAMTS13 CUB domain mutation, we performed clinical exome sequencing using a custom capture kit to achieve high sequencing coverage for the target genes of interest. These genes included ADAMTS13 (37 Kb), vWF (176 Kb), alternative complement pathway genes (CFH (95 Kb), CFI (61 Kb), CFB (24 Kb), C3 (53 Kb), CD46 (43 Kb)), lectin complement pathway gene (MBL2 (6.3 Kb)) and genes recently described in familial NCIPH (KCNN3 (173 Kb) and DGUOK (32 Kb)), and immunostaining for ADAMTS13 on liver biopsy.
Case recruitment
Consecutive NCIPH patients visiting the liver clinic were recruited as cases. Healthy volunteers served as healthy controls. NCIPH was diagnosed as per published criteria-all patients had gastroesophageal varices on endoscopy, patent portal vein, and hepatic venous outflow tract on Doppler ultrasound, an unyielding detailed evaluation for known etiologies of liver disease and liver biopsy showing the absence of advanced fibrosis and absence of findings suggesting alternate etiology, e.g. autoimmune hepatitis, etc. Diseases, known to histologically mimic NCIPH (e.g. sarcoidosis, schistosomiasis, etc.), were excluded [3] .
Twenty-four NCIPH patients were recruited for the study. The route of the liver biopsy was transjugular, 9 patients; percutaneous, 7; and per-operative, 8 (tru-cut and wedge biopsies of the liver obtained during splenorenal shunt surgery (7) and splenectomy (1)). On transjugular liver biopsy, 3 (2-7); median (range) cores of the liver with maximum size 11.5 (3-13) mm and containing 7 (5-13) portal tracts were obtained. Similarly, on percutaneous liver biopsy, 2 (1-3) cores of the liver of maximum size 15.5 (10-19) mm and containing 7 (5-19) portal tracts were obtained. On liver biopsy, 14 patients had mild portal fibrosis and 4 had no portal fibrosis, 5 had focal bridging fibrosis.
Besides evaluation of the severity of liver disease in patients with NCIPH, all study participants underwent assays to determine the plasma ADAMTS13-vWF balance, plasma Pselectin (protein anchoring vWF to the endothelial surface), and also evaluation for mutation in the CUB domain of the ADAMTS13 gene.
Assays of plasma levels of ADAMTS13, vWF, and P-selectin in a cohort of NCIPH patients Plasma levels of ADAMTS13, vWF, and P-selectin were tested on citrated platelet poor plasma stored at −80°C until assay. ADAMTS13 FRET activity, vWF antigen/activity, and Pselectin concentrations were estimated by commercially available kits from American Diagnostica Inc., Hyphen BioMed, and R&D Systems, respectively. ADAMTS13 activity was assessed by two methods-the fluorescence resonance energy transfer (FRET) method which measures the increase in fluorescence when ADAMTS13 uncouples the recombinant -VWF86 ALEXA FRET substrate and also by measuring residual collagen binding activity of purified vWF concentrate (in-house collagen binding assay, CBA) as was previously described [13] .
The manufacturer's normal ranges for the plasma ADAMTS13 antigen, ADAMTS13 FRET activity, vWF antigen, and P-selectin were 740±110 ng/mL, 50% to 150%, 0.5-1.5 IU/mL, and 18-40 ng/mL, respectively. The vWF antigen and ADAMTS13 antigen were converted to a percentage of normal plasma for calculation of the vWF/ADAMTS13 ratio.
Sequencing the CUB domain of the ADAMTS13 gene in a cohort of NCIPH patients Genomic DNA was isolated from the blood of 17 NCIPH patients as well as from 3 healthy controls using the QIAGEN DNA extraction kit as described by the manufacturer. Genomic DNA (100 ng) was utilized to amplify exons 26 and 27 pertaining to the CUB domain of the ADAMTS13 gene (9q34). The PCR reaction mixture (50 μL) containing 25 μLTaq DNA polymerase, 2× Master Mix Red, and forward (5′ ACA GGG TCC ACC CCT ACC T 3′) and reverse (5′ CCC AGT TCC TTC CAT CTC AG 3′) primers (4 pmol each) were used as described previously. The PCR conditions were initial denaturation at 95°C for 2 min followed by 35 cycles of 95°C for 30 s, 56°C for 30 s, 72°C for 1 min, and final extension at 72°C for 5 min. The successful amplification was evident by visualization of a specific 901-bp PCR product on agarose gel electrophoresis after staining with ethidium bromide.
Purified PCR products (901 bp) was sequenced both in the sense and anti-sense orientation using the Big Dye Terminator V3.1 cycle sequencing kit in a 3130 Genetic Analyzer from AB Applied Biosystems. The sequence was analyzed for mutations using the NovoSNP software.
RFLP for the R1277W mutation in a cohort of NCIPH patients RFLP for the detected ADAMTS13-CUB domain variant (R1277W) was performed in all 24 NCIPH patients and 22 healthy controls. PCR products were digested with the restriction endonuclease BalI to identify the R1277W variant. The purified PCR product (~1 μg) was digested by BalI (2 units) at 37°C for 2 h, and the digested products were separated by agarose gel (2% (W/V)) electrophoresis.
Clinical exome sequencing and immunostaining of liver biopsy for ADAMTS13 in one NCIPH patient with the ADAMTS13 R1277W variant
To preclude other causative mutations, clinical exome sequencing was carried out in one NCIPH patient (who had the ADAMTS13 R1277W variant). Exome capture was performed on 50 ng of genomic DNA sample using Nextera Rapid Capture custom enrichment. The library was sequenced at a mean coverage of > 80-100X on the Illumina sequencing platform. The sequences obtained were aligned to the human reference genome (GRCh37/hg19) using the BWA tool, and the variant calling was performed using GATK-Lite based tools. Further, the annotation of variants identified was carried out against the Ensemble release 75 gene model. Ninety-eight percent of the coding region of ADAMST13 was covered by the sequencing process with 96.1% of the reads of quality ≥ Q30. Further, validation of the sequencing data analysis to identify variations in target genes of interest pertaining to ADAMTS13-vWF axis (ADAMTS13, vWF), alternative/ lectin complement pathways (CFH, CD46, CFI, CFB, C3, MBL2), and genes recently described associated with familial NCIPH (KCNN3 and DGUOK) was carried out using the DNA Star software (DNASTAR, Inc. Madison, WI, USA).
Indirect immunofluorescence technique was used to immunostain the liver biopsy of this NCIPH patient using a commercial rabbit polyclonal antibody to ADAMTS13 (H-300, Santa-Cruz Biotechnology, Inc). The nuclei were labeled by 4′,6-diamidino-2-phenylindole (DAPI) and stellate cells were stained with glial fibrillary acidic protein (GFAP).
Statistical analysis
Variables were expressed as numbers (percentage) or median (range) as appropriate. Non-parametric tests (Mann-Whitney U, Wilcoxon signed ranks test, Fisher's exact test, or chisquare test) were used for comparison and a p-value of ≤0.05 was considered as statistically significant. The study was approved by the institutional ethics committee.
Results
Twenty-four NCIPH patients and 22 healthy controls were recruited for this study. Table 1 depicts the regional distribution, demographics, and baseline characteristics of the study participants. All NCIPH patients were in Child's class A (23 patients) or B (1 patient). There was no family history of liver disease in NCIPH patients.
Twenty-one of the 24 NCIPH patients had thrombocytopenia-severe (<50,000/cmm), 6; moderate (50,000/cmm-75,000/cmm), 4; and mild (75,000/cmm-1,50,000/cmm), 11. Three of the 20 (15%) patients tested had low serum vitamin B 12 levels (<200 pg/mL). Hepatic venous pressure gradient measured in 11 NCIPH patients was 7 (5-18) mmHg, median (range). In two patients, HVPG was ≤5 mmHg. One NCIPH patient each had associated celiac disease and arsenicosis.
Plasma ADAMTS13-vWF levels in a cohort of NCIPH patients and in controls: vWF antigen in 23 NCIPH patients (1.8, 1-5.3 IU/mL; median, range) was significantly higher than in 18 healthy controls (0.9, 0.4-1.66 IU/mL; p-value <0.001), Fig. 1 .
The plasma ADAMTS13 antigen in the 15 NCIPH patients (486, 239-614 ng/mL, median, range) was significantly lower than in the 18 healthy controls (753, 394-107 ng/mL; p-value <0.001). Figure 1 also depicts the deranged vWF/ ADAMTS13 ratio in NCIPH patients (2.4, 1.2-6.5) as compared to healthy controls (0.9, 0.5-1.8; p-value <0.001). Figure 2 depicts the plasma ADAMTS13 activity as assayed by FRET and collagen binding assays in NCIPH patients (76%, 39% to 136% and 66%, 10% to 105%) as compared to healthy controls (110%, 63% to 161% and 104%, antigen levels were available in 23 NCIPH patients and 18 healthy controls; ADAMTS13 antigen levels were available in 15 NCIPH patients and 18 healthy controls 83% to 122%), respectively. In both these assays, the ADAMTS13 activity was significantly lower in NCIPH patients (p-value 0.008 and p-value <0.001) as compared to healthy controls. In NCIPH patients, there was a trend to lower ADAMTS13 activity by collagen binding assay (CBA) as compared to ADAMTS13 activity by FRET assay. One NCIPH patient (Child's score 6) had severe ADAMTS13 deficiency (ADAMTS13 activity by CBA <10%) and six NCIPH patients (Child's score 5 in four patients and Child's score 6 in 2 patients) had a mild ADAMTS13 deficiency (ADAMST13 activity by CBA ≤55%). None of the healthy controls had deficient ADAMTS13 activity by CBA.
P-selectin levels in a cohort of NCIPH patients and in controls Plasma P-selectin levels were similar in 15 NCIPH patients (39 ng/mL, 5-144 ng/mL, median, range) and 9 healthy controls (34 ng/mL, 8-41 ng/mL; p-value 0.5); 7/15 NCIPH patients had high plasma P-selectin levels, i.e. >40 ng/mL as compared to 1/9 healthy controls (p-value 0.2).
Mutation analysis in the CUB domain of the ADAMTS13 gene in a cohort of NCIPH patients Sequencing of the CUB domain was done in 17 NCIPH patients and 3 healthy controls. One NCIPH patient showed a rare nucleotide change at position c.3829C >T resulting in p.R1277W (rs14045669).
We further performed BalI RFLP analysis targeted to R1277W variant detection in all 24 NCIPH patients and 22 healthy controls (including the subjects in whom sequencing was done). Except for one NCIPH patient with R1277W variant on sequencing, no other subjects had this variant, Fig. 3 .
Clinical exome sequencing variant analysis in one NCIPH patient with the ADAMTS13 R1277W variant
No reported pathogenic variants were identified by clinical exome sequencing in this patient. However, further analysis of the clinical exome sequence data for the target genes of interest detected the presence of several nucleotide changes including heterozygous missense variants (p.R1277W and p.Q448E) in the ADAMTS13 gene and also in CFI, CFB, CFH, and vWF genes ( Table 2 ). All observed missense variants were predicted to be polymorphisms or benign by bioinformatic tools Polyphen-2, SIFT, and Mutation taster (www. mutationtaster.org). Only the R1277W variant (dbSNP rs140450669) in the ADAMTS13 gene was found to be rare and was reported in the ExAc database (Exome Aggregation consortium) with an allelic frequency of 0.017% in South Asians and 0.002% in Europeans. Details of the nonsynonymous variants are given in Table 2 . The list of all variants in the genes of interest is provided as supplementary material.
Immunostaining of liver biopsy in one NCIPH patient with the ADAMTS13 R1277W variant
On immunostaining of normal liver tissue, we demonstrated co-localization of ADAMTS13 and GFAP (which stains liver stellate cells). On studying the ADAMTS13 immunostained liver biopsy slides, on light microscopy, unlike normal/ cirrhotic control, more punctate and diffuse ADAMTS13 staining, and under high power, globules of ADAMTS13 were seen in stellate cells (Fig. 4) .
Clinical details of the NCIPH patient with the ADAMTS13 R1277W variant
A 21-year-old male, born to non-consanguineous parentage, belonging to the lower socioeconomic class (as assessed by modified Kuppuswamy score), residing in northern India, presented with splenomegaly since 10 years of age and hematemesis at the age of 17 years. He had no family history of similar illness. He underwent proximal splenorenal shunt surgery in 2012. Perioperative liver biopsy showed mild portal fibrosis. He developed glomerulonephritis (renal biopsy suggesting C3 nephritis) 15 months after the shunt surgery and was treated unsuccessfully with steroids. He developed secondary portal vein thrombosis and had worsening kidney function on follow up. He suffered from two episodes of spontaneous bacterial peritonitis and subsequently was on maintenance hemodialysis from 2.5 years after the shunt surgery. Repeat kidney biopsy revealed diffuse, proliferative sclerosing glomerulonephritis with deposits of IgA, IgG, IgM, and C3.
He had low ADAMTS13 activity (lowest level CBA,10%; FRET, 68.3%) and high vWF antigen levels at the initial visit (5.33 IU/mL) in the plasma. The subsequent ADAMTS13 levels were within normal range, but vWF activity assessed by collagen binding assay remained high (2.9xULN (2.6-3.5xULN), median, range), Table 3 . Plasma P-selectin levels were high (100 ng/mL). He had platelet counts in the normal range (post-splenectomy status) and had no features suggesting microangiopathy (like schistocytes in peripheral blood smear) in the systemic circulation. Total complement activity was low (60%, normal 80% to 96%) with low C3 (76 mg/dL, normal 90-180 mg/dL) and preserved C4 (11.4 mg/dL, normal 10-140 mg/dL), suggesting possible activation of the alternative complement pathway. There was no inflammation on duodenal biopsy and anti-tissue transglutaminase antibody was negative. There were no skin changes suggesting arsenicosis, but nail arsenic levels were not tested.
Discussion
NCIPH is a relatively common cause of unexplained portal hypertension in India [1, 2] . Our two previous reports from India and the UK have demonstrated low ADAMTS13 MAF minor allele frequency, PP2 polyphen 2, BEN benign, POS DAM possibly damaging, SIFT sorting intolerant from tolerant, Tol tolerable, Del deleterious, MT mutation taster, Poly polymorphism, ADAMTS13 disintegrin like and metalloproteinase with thrombospondin type 1 motifs-13, vWF von Willebrand factor, CFB complement factor B, CFI complement factor I, CFH complement factor H activity, especially with collagen binding activity assay, in NCIPH patients despite preserved liver function. The present study also reiterates this finding, with all three studies demonstrating lower activity with the ADAMTS13-CBA assay (activity against the complete vWF molecule) compared to the ADAMTS13-FRET assay (activity against vWF peptide fragment having the cleaving site). This suggests relatively preserved specific vWF cleaving activity of ADAMTS13, prompting us to embark on a study to assess exons pertaining to the CUB domain (thought to be responsible for the initial binding of ADAMTS13 to vWF) of the ADAMTS13 gene.
In this study, of the 24 NCIPH patients, we found mutations in the CUB domain of ADAMTS13 in a single patient. This patient had severely deficient ADAMTS13 collagen binding activity (on single occasion), consistently raised vWF, and retention of ADAMTS13 globules in the hepatic stellate cells. Immunostaining of the liver biopsy strongly suggests a defect in ADAMTS13 secretion. His plasma vWF activity, on four occasions, was elevated 2.6-3.5 times the upper limit of normal. Hence, this rare variant (p.R1277W) in exon 27, pertaining to the CUB domain of the ADAMTS13 gene, might have a role in defective ADAMTS13 protein secretion which has to be functionally validated. Deletions in exon 27 (pertaining to the CUB domain) of ADAMTS13 has also been noted in one patient with hereditary TTP [14] .
Neither the other NCIPH patients nor the healthy controls had any detectable mutation in the ADAMTS13 CUB domain. The functional significance of this mutation needs to be further characterized. In order to understand the possibility of other genes' involvement in NCIPH, we performed clinical exome sequencing in this NCIPH patient with ADAMTS13 CUB domain (p.R1277W) mutation. Another missense variant in ADAMTS13 gene Q448E (rs2301612, cysteine-rich region) was also identified in this patient. This SNP has been previously reported in families with congenital thrombotic thrombocytopenic purpura (TTP) [15] . Allele frequency of rs2301612 was 19% (tested in 364 healthy subjects from Japan [16] ). The frequency of this polymorphism in the Indian population needs to be characterized. Though in the study by Kokame and Miyata [15] no functional impact of this mutation (rs2301612) was noted on vWF cleaving activity, it has been shown that along with other ADAMTS13 mutations, it can modulate ADAMTS13 protein expression and activity [17] . This variation has been shown to have a deleterious impact on other vascular pathology, e.g. cerebral aneurysms [17] .
Altered vWF-ADAMTS13 balance is noted in advanced stages of cirrhosis and may be involved in the progression of disease [18] [19] [20] . In NCIPH patients, we have noted deficient ADAMTS13 activity in patients with preserved liver function, suggesting a role in the pathogenesis of intrahepatic portal venous occlusion [3, 4] . Table 2 lists the various non-synonymous variants noted in the NCIPH patient on targeted exome sequencing of the genes of interest (pertaining to ADAMTS13-vWF, alternative and lectin complement pathways, DGUOK, and KCNN3). Besides the R1277W variation, there were rare variants (minor allele frequency of < 0.5% [21] ) noted in alternative complement pathways (CFI and CFH). Though none of these variants have previously been associated with NCIPH, the effect of combined burden of these variants is unclear. It is expected that rare variants are more likely to confer risks for a disease process and same needs to be further studied [22] .
The other variants in CFH and CFB (rs1061170 and rs12614, respectively) have been previously reported with uncertain significance in atypical hemolytic uremic syndrome, another form of thrombotic microangiopathy. Previous studies also describe other variations in complement genes in patients with congenital TTP and hemolytic uremic syndrome [23] .
Acquired or inherited deficiency of ADAMTS13 results in accumulation of ultra-large vWF multimers, which in turn predisposes platelet adhesion to the endothelium [24] [25] [26] . ADAMTS13 deficiency is implicated in TTP and its role in various other thrombotic conditions is under study [27, 28] . Genetic variations in ADAMTS13 can result in the inherited form of severe TTP (Upshaw-Schulman Syndrome) or may result in partial ADAMTS13 activity loss predisposing to various thrombotic events [8, [29] [30] [31] [32] .
ADAMTS13 deficiency may trigger complement activation in patients with thrombotic microangiopathy [9] . In addition to low ADAMTS13, activation of the alternative complement pathway is an important mechanism for thrombotic microangiopathy.
Also, there were recent reports of single gene mutations in DGUOK [12] and KCNN3 [11] , implicated in familial NCIPH inherited in autosomal recessive/dominant manner, respectively. We did not find any variations in these genes in a single NCIPH patient.
Unlike the autosomal dominant/recessive inheritance noted in some of the studies, none of our NCIPH patients in this study had a family history of similar liver disease. This suggests that NCIPH, in most patients, is a complex disorder, where a genetically predisposed individual when challenged by an environmental risk factor develops localized portal vasculopathy. Thus, either a shared genetic predisposition or a shared environmental insult could be responsible for the increased prevalence of NCIPH in India and other developing countries [33] . As the pathology is limited to portal microcirculation, in previous studies, we looked at the role of the gut in the pathogenesis of NCIPH. There was an increased prevalence of non-specific gut inflammation [34] , celiac disease, and gut-derived toxins (arsenicosis) [35] in these patients. In the present study, one NCIPH patient each had arsenicosis and celiac disease.
As in our previous report [36] , in this study, also 15% of NCIPH patients had low serum vitamin B 12 levels. In India, with endemic vitamin B 12 deficiency, presence of vitamin B 12 deficiency in patients with unexplained portal hypertension is a marker of absence of advanced fibrosis and NCIPH [37] . It is unclear if this association has any causative implications in the pathogenesis of NCIPH.
Worsening vWF-ADAMT13 imbalance is noted with advancing stages of cirrhosis [19, 20] . This may contribute to focal parenchymal extinction in the liver noted in these patients and consequently important in the progression of disease [38] . Altered vWF-ADAMTS13 balance may also play a role in pro-thrombotic mileu noted in cirrhotics [39] . There is scope for wide ranging therapeutic potential targeting the vWF-ADAMTS13 imbalance to treat NCIPH in particular and portal hypertension in general [40] .
Thus, in our study, we demonstrate missense variants in ADAMTS13, vWF, and complement genes in a single patient with NCIPH, associated with decreased secretion and activity of ADAMTS13 protein. Further research in this area is warranted.
